At a recent UCSF stem cell gathering, Diabetes Center Director Jeffrey Bluestone, PhD compared the effort of transforming stem cells to beta cells to a coast-to-coast road trip from San Francisco to New York. According to Dr. Bluestone, “We’re not in New York yet, but we’re getting close. We’re in Newark.”
Michael McManus, PhD is UCSF’s resident expert in microRNAs, the so called “dark matter” of the genome that are the tiny “switches” that control most of the genes in the body.
UCSF pediatric endocrinologist Robert Lustig is frustrated by the food industry's marketing wars involving sugar. As the public learns more about the dangers of high fructose corn syrup (HFCS), the food industry is turning back to sucrose (cane or beet sugar), using the marketing tactic that sucrose is "natural" and therefore somehow "healthier.”
The Diabetes Center at UCSF is proud of its partnership with diabetes researchers and clinicians across all UCSF campuses, hospitals and research centers. These complementary “neighborhoods” are helping to drive research in numerous directions – all focused on improving the lives of those living with diabetes.
Thanks to the generosity of Bobbie and Mike Wilsey who helped to create a clinical fellowship at UCSF, Dr. Bonnie Kimmel is nearing completion of an extraordinary year serving as the first UCSF Wilsey Fellow.
Dr. Larry Fisher is on a quest to learn who and why some type 2 patients experience affective and anxiety disorders, depressive affect and diabetes-related distress over time – and some do not.
UCSF researchers are often honored by the diabetes community for their significant scientific achievements. It is equally meaningful when our clinicians receive well-deserved recognition for the passionate care they provide to families, and for their cutting-edge clinical research efforts.
Researchers at the Barbara Davis Center in Denver have identified a fourth autoantibody to help predict type 1 diabetes, ZnT8. This autoantibody, in combination with the others that had been previously identified, has raised our ability to detect “pre-diabetes” to 98 percent.
In December, the Institute for Regeneration Medicine at UCSF was renamed the Eli and Edythe Broad Center of Regeneration Medicine at a press conference attended by Governor Arnold Schwarzenegger, Chair of the California Institute for Regenerative Medicine (and Diabetes Center Leadership Council Member) Robert Klein, generous philanthropists Eli and Edythe Broad, and university leaders.
UCSF Pediatric Diabetes Program Director Steve Gitelman, MD has partnered with the Immune Tolerance Network (ITN) to launch a study involving ATG , or anti-thymocyte globulin, to see if this drug can halt the progression of new onset type 1 diabetes. The START trial (Study of Thymoglobulin to Arrest Type 1 Diabetes) hopes to recruit 66 volunteers, 18 – 35 years of age, within six weeks of diagnosis.
On November 20, UCSF held a panel discussion on stem cell research that was moderated by KQED Radio’s Michael Krasny, PhD. Diabetes Center researcher Matthias Hebrok, PhD joined an esteemed group of stem cell researchers to discuss the potential of stem cells to cure disease. [ Forum, KQED ]
Two common cancer drugs have been shown to both prevent and reverse type 1 diabetes in a mouse model of the disease, according to research conducted at the University of California, San Francisco. The drugs – imatinib (marketed as Gleevec) and sunitinib (marketed as Sutent) – were found to put type 1 diabetes into remission in 80 percent of the test mice and work permanently in 80 percent of those that go into remission.
In recent breakthroughs, researchers have developed a process for reprogramming fully grown adult cells back into something akin to embryonic stem cells, called induced pluripotent stem cells, or iPS cells.